GlassScriptPhysician profile
William L Yap
NPI 1568438802
$6,268.04
in general payments reported to CMS, 2019-2025
18 companies · $23.72 in 2025
The $23.72 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,928 · 2020: $587 · 2021: $730 · 2025: $23.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,142.47 | 2019-2025 | |
| Amgen INC. | $539.68 | 2019-2021 | |
| Janssen Biotech, INC. | $233.32 | 2019-2021 | |
| Lilly USA, LLC | $214.14 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $184.68 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $171.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $167.84 | 2019-2021 | |
| Gilead Sciences, INC. | $124.47 | 2019 | |
| Ucb, INC. | $111.78 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.91 | 2019 | |
| Horizon Therapeutics Plc | $61.43 | 2019-2020 | |
| Pfizer INC. | $57.95 | 2019-2021 | |
| Celgene Corporation | $41.64 | 2019 | |
| Mallinckrodt Enterprises LLC | $35.92 | 2019 | |
| Hikma Pharmaceuticals USA | $25.73 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $20.73 | 2019 | |
| Genentech USA, INC. | $19.14 | 2019 | |
| Medexus Pharma, INC. | $14.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Yap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.